Emmaus Fumes After EMA Rejects Sickle Cell Drug Again
Executive Summary
The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP, Emmaus may try the decentralized approval procedure instead.
Topics
- Subjects
- Drug Review
- Market Access
- Approvals
- Strategy
- Rare Diseases
- Therapy Areas
- Blood & Coagulation Disorders
- Regions
- Europe
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125887
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC125887
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.